Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Thumbnail image for 118-0066-1
Case
-
Reference no. 118-0066-1
Published by:
IBS Center for Management Research (2018)
Length:
8 pages
Data source:
Published sources

Abstract

On November 7, 2017, the Lupin stock hit a 52-week low of INR846.20 when the pharma major informed the NSE and the BSE about the warning letter it had received from the USFDA. Following the steep decline in the stock price, company's market valuation eroded by INR78.66 billion. Concerned over Lupin Ltd's margins, most of the brokerage houses cut their target price on the stock. Investors were left wondering whether they should sell the stock, hold it, or buy more. The present case uses the backdrop of Lupin stock price fluctuations to teach the concept of risk and return analysis.

Topics

Risk and return of stock; Market return and risk; Historical return and risk; Expected return and risk; Beta; CAPM; Overpriced; Under priced
Location:
Industry:
Size:
Very Large
Other setting(s):
2008-2017

Access this item

casecent.re/p/154976
View our pricing guide
or to see prices.

Reviews & usage